Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3437]

Comment: Sacituzumab govitecan for HR+/HER2‐ advanced breast cancer

Dr Jane Lowe Meisel - Winship Cancer Institute of Emory University, Georgia, USA

Comment: Sacituzumab govitecan for HR+/HER2‐ advanced breast cancer ( Dr Jane Lowe Meisel - Winship Cancer Institute of Emory University, Georgia, USA )

Circulating tumour DNA analysis can help identify the need for adjuvant therapy...

Dr Jeanne Tie - Peter MacCallum Cancer Centre, Melbourne, Australia

Circulating tumour DNA analysis can help identify the need for adjuvant therapy in stage II colon cancer ( Dr Jeanne Tie - Peter MacCallum Cancer Centre, Melbourne, Australia )

Sacituzumab govitecan increases PFS for HR+/HER2- metastatic breast cancer

Dr Hope Rugo - University of California San Francisco, San Francisco, USA

Sacituzumab govitecan increases PFS for HR+/HER2- metastatic breast cancer ( Dr Hope Rugo - University of California San Francisco, San Francisco, USA )

Ramucirumab plus pembrolizumab improves OS in advanced NSCLC

Dr Roy Herbst - Yale Cancer Center, New Haven, USA

Ramucirumab plus pembrolizumab improves OS in advanced NSCLC ( Dr Roy Herbst - Yale Cancer Center, New Haven, USA )

Cancer Services Delivery: Focus on India

Dr Soumitra Datta - Tata Medical Center, Kolkata, India

Cancer Services Delivery: Focus on India ( Dr Soumitra Datta - Tata Medical Center, Kolkata, India )

COMy 2022: Multiple myeloma roundup

Prof Philippe Moreau - University Hospital of Nantes, Nantes, France

COMy 2022: Multiple myeloma roundup ( Prof Philippe Moreau - University Hospital of Nantes, Nantes, France )

Giving abatacept after checkpoint inhibitors can improve immunotherapy...

Dr Stephen Mok - The University of Texas MD Anderson Cancer Center, Houston, USA

Giving abatacept after checkpoint inhibitors can improve immunotherapy responses in melanoma ( Dr Stephen Mok - The University of Texas MD Anderson Cancer Center, Houston, USA )

Long-term outcomes with sotorasib in pretreated KRASp.G12C-mutated NSCLC: 2...

Dr Grace Dy - Roswell Park Comprehensive Cancer Center, Buffalo, USA

Long-term outcomes with sotorasib in pretreated KRASp.G12C-mutated NSCLC: 2-year analysis of CodeBreaK100 ( Dr Grace Dy - Roswell Park Comprehensive Cancer Center, Buffalo, USA )

Nivolumab plus platinum-doublet chemo vs chemo as neoadjuvant treatment for...

Prof Nicolas Girard - Institut Curie, Paris, France

Nivolumab plus platinum-doublet chemo vs chemo as neoadjuvant treatment for resectable NSCLC ( Prof Nicolas Girard - Institut Curie, Paris, France )

Advance Prostate Cancer Consensus Conference 2021: Report

Prof Silke Gillessen and Prof Aurelius Omlin

Advance Prostate Cancer Consensus Conference 2021: Report ( Prof Silke Gillessen and Prof Aurelius Omlin )

Recent advances in the treatment of patients with exon 20 insertion-positive...

Dr Alfredo Addeo, Prof Nicolas Girard and Prof Natasha Leighl

Recent advances in the treatment of patients with exon 20 insertion-positive NSCLC ( Dr Alfredo Addeo, Prof Nicolas Girard and Prof Natasha Leighl )

Intratumoral BO-112 with pembrolizumab shows benefit in advanced melanoma...

Dr Iván Márquez-Rodas - Hospital General Universitario Gregorio Marañón, Madrid...

$Intratumoral BO-112 with pembrolizumab shows benefit in advanced melanoma refractory to anti-PD-1 therapy ( Dr Iván Márquez-Rodas - Hospital General Universitario Gregorio Marañón, Madrid, Spain )$

More from ecancer